{"title":"碘-123 甲碘苄胍原发肿瘤标准化摄取值对预测嗜铬细胞瘤和副神经节瘤转移潜力的实用性","authors":"Mitsuho Hirahara, Masatoyo Nakajo, Ikumi Kitazano, Megumi Jinguji, Atsushi Tani, Koji Takumi, Kiyohisa Kamimura, Akihide Tanimoto, Takashi Yoshiura","doi":"10.1007/s11307-024-01952-8","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>To examine the usefulness of semi-quantitative analysis using the standardized uptake value (SUV) of iodine-123 metaiodobenzylguanidine ([<sup>123</sup>I]-MIBG) for predicting metastatic potential in patients with pheochromocytoma (PHEO) and paraganglioma (PGL).</p><h3 data-test=\"abstract-sub-heading\">Procedures</h3><p>This study included 18 PHEO and 2 PGL patients. [<sup>123</sup>I]-MIBG visibility and SUV-related parameters (SUVmax, SUVmean, tumor volume of [<sup>123</sup>I]-MIBG uptake [TV_MIBG], and total lesion [<sup>123</sup>I]-MIBG uptake) were compared with the pathological grading obtained using the Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and the Grading System for Adrenal Pheochromocytoma and Paraganglioma (GAPP), which are used to predict metastatic potential. The PASS scores were categorized as < 4 and ≥ 4. Based on the GAPP scores, PHEOs/PGLs were categorized as follows: well, moderately, and poorly differentiated tumors. The Mann–Whitney U test or Spearman’s rank correlation was used to assess differences or associations between two quantitative variables.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>All PHEOs/PGLs were visualized on [<sup>123</sup>I]-MIBG scintigraphy. There were 16 PASS < 4 and 4 PASS ≥ 4 tumors. Moreover, 11 and 9 tumors were well and moderately differentiated, respectively. The uptake scores and SUV-related parameters significantly differed between tumors with a PASS score of < 4 and those with a PASS score of ≥ 4 (each, <i>p</i> > 0.05). Moderately differentiated tumors had significantly higher uptake scores and SUV-related parameters except TV_MIBG than well-differentiated tumors (each, <i>p</i> < 0.05). The GAPP score was positively correlated with the uptake scores and SUV-related parameters (each, <i>p</i> < 0.05) except TV_MIBG.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>The primary tumor [<sup>123</sup>I]-MIBG uptake assessed using SUV-related parameters can be an imaging tool for predicting metastatic potential in patients with PHEO/PGL.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":"44 1","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Usefulness of the Primary Tumor Standardized Uptake Value of Iodine-123 Metaiodobenzylguanidine for Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma\",\"authors\":\"Mitsuho Hirahara, Masatoyo Nakajo, Ikumi Kitazano, Megumi Jinguji, Atsushi Tani, Koji Takumi, Kiyohisa Kamimura, Akihide Tanimoto, Takashi Yoshiura\",\"doi\":\"10.1007/s11307-024-01952-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Purpose</h3><p>To examine the usefulness of semi-quantitative analysis using the standardized uptake value (SUV) of iodine-123 metaiodobenzylguanidine ([<sup>123</sup>I]-MIBG) for predicting metastatic potential in patients with pheochromocytoma (PHEO) and paraganglioma (PGL).</p><h3 data-test=\\\"abstract-sub-heading\\\">Procedures</h3><p>This study included 18 PHEO and 2 PGL patients. [<sup>123</sup>I]-MIBG visibility and SUV-related parameters (SUVmax, SUVmean, tumor volume of [<sup>123</sup>I]-MIBG uptake [TV_MIBG], and total lesion [<sup>123</sup>I]-MIBG uptake) were compared with the pathological grading obtained using the Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and the Grading System for Adrenal Pheochromocytoma and Paraganglioma (GAPP), which are used to predict metastatic potential. The PASS scores were categorized as < 4 and ≥ 4. Based on the GAPP scores, PHEOs/PGLs were categorized as follows: well, moderately, and poorly differentiated tumors. The Mann–Whitney U test or Spearman’s rank correlation was used to assess differences or associations between two quantitative variables.</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>All PHEOs/PGLs were visualized on [<sup>123</sup>I]-MIBG scintigraphy. There were 16 PASS < 4 and 4 PASS ≥ 4 tumors. Moreover, 11 and 9 tumors were well and moderately differentiated, respectively. The uptake scores and SUV-related parameters significantly differed between tumors with a PASS score of < 4 and those with a PASS score of ≥ 4 (each, <i>p</i> > 0.05). Moderately differentiated tumors had significantly higher uptake scores and SUV-related parameters except TV_MIBG than well-differentiated tumors (each, <i>p</i> < 0.05). The GAPP score was positively correlated with the uptake scores and SUV-related parameters (each, <i>p</i> < 0.05) except TV_MIBG.</p><h3 data-test=\\\"abstract-sub-heading\\\">Conclusions</h3><p>The primary tumor [<sup>123</sup>I]-MIBG uptake assessed using SUV-related parameters can be an imaging tool for predicting metastatic potential in patients with PHEO/PGL.</p>\",\"PeriodicalId\":18760,\"journal\":{\"name\":\"Molecular Imaging and Biology\",\"volume\":\"44 1\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Imaging and Biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11307-024-01952-8\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-024-01952-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
摘要
目的研究使用碘-123偏碘苄基胍([123I]-MIBG)的标准化摄取值(SUV)进行半定量分析对预测嗜铬细胞瘤(PHEO)和副神经节瘤(PGL)患者的转移可能性的实用性。将[123I]-MIBG能见度和SUV相关参数(SUVmax、SUVmean、[123I]-MIBG摄取的肿瘤体积[TV_MIBG]和病变[123I]-MIBG总摄取量)与使用肾上腺嗜铬细胞瘤标度评分(PASS)和肾上腺嗜铬细胞瘤和副神经节瘤分级系统(GAPP)获得的病理分级进行比较,这两个系统用于预测转移潜力。PASS评分分为< 4和≥4。根据 GAPP 评分,PHEOs/PGL 被分为:良好分化、中度分化和差分化肿瘤。采用 Mann-Whitney U 检验或 Spearman 秩相关检验评估两个定量变量之间的差异或相关性。其中有 16 个 PASS < 4 和 4 个 PASS ≥ 4 肿瘤。此外,分化良好和中度分化的肿瘤分别有11个和9个。PASS评分为< 4的肿瘤与PASS评分≥4的肿瘤之间的摄取评分和SUV相关参数有明显差异(均为P> 0.05)。中度分化肿瘤的摄取评分和 SUV 相关参数(TV_MIBG 除外)明显高于分化良好的肿瘤(两者均为 p <0.05)。结论使用SUV相关参数评估原发肿瘤[123I]-MIBG摄取量可作为预测PHEO/PGL患者转移可能性的成像工具。
Usefulness of the Primary Tumor Standardized Uptake Value of Iodine-123 Metaiodobenzylguanidine for Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma
Purpose
To examine the usefulness of semi-quantitative analysis using the standardized uptake value (SUV) of iodine-123 metaiodobenzylguanidine ([123I]-MIBG) for predicting metastatic potential in patients with pheochromocytoma (PHEO) and paraganglioma (PGL).
Procedures
This study included 18 PHEO and 2 PGL patients. [123I]-MIBG visibility and SUV-related parameters (SUVmax, SUVmean, tumor volume of [123I]-MIBG uptake [TV_MIBG], and total lesion [123I]-MIBG uptake) were compared with the pathological grading obtained using the Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and the Grading System for Adrenal Pheochromocytoma and Paraganglioma (GAPP), which are used to predict metastatic potential. The PASS scores were categorized as < 4 and ≥ 4. Based on the GAPP scores, PHEOs/PGLs were categorized as follows: well, moderately, and poorly differentiated tumors. The Mann–Whitney U test or Spearman’s rank correlation was used to assess differences or associations between two quantitative variables.
Results
All PHEOs/PGLs were visualized on [123I]-MIBG scintigraphy. There were 16 PASS < 4 and 4 PASS ≥ 4 tumors. Moreover, 11 and 9 tumors were well and moderately differentiated, respectively. The uptake scores and SUV-related parameters significantly differed between tumors with a PASS score of < 4 and those with a PASS score of ≥ 4 (each, p > 0.05). Moderately differentiated tumors had significantly higher uptake scores and SUV-related parameters except TV_MIBG than well-differentiated tumors (each, p < 0.05). The GAPP score was positively correlated with the uptake scores and SUV-related parameters (each, p < 0.05) except TV_MIBG.
Conclusions
The primary tumor [123I]-MIBG uptake assessed using SUV-related parameters can be an imaging tool for predicting metastatic potential in patients with PHEO/PGL.
期刊介绍:
Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures.
Some areas that are covered are:
Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes.
The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets.
Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display.
Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging.
Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics.
Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations.
Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.